ZA9710737B - Methods for preventing graft rejection in transplantation and for procuding a universal gene therapy host cell - Google Patents

Methods for preventing graft rejection in transplantation and for procuding a universal gene therapy host cell

Info

Publication number
ZA9710737B
ZA9710737B ZA9710737A ZA9710737A ZA9710737B ZA 9710737 B ZA9710737 B ZA 9710737B ZA 9710737 A ZA9710737 A ZA 9710737A ZA 9710737 A ZA9710737 A ZA 9710737A ZA 9710737 B ZA9710737 B ZA 9710737B
Authority
ZA
South Africa
Prior art keywords
procuding
transplantation
methods
host cell
gene therapy
Prior art date
Application number
ZA9710737A
Other languages
English (en)
Inventor
Mauro Biffoni
Ruben Papoian
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of ZA9710737B publication Critical patent/ZA9710737B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9710737A 1996-11-29 1997-11-28 Methods for preventing graft rejection in transplantation and for procuding a universal gene therapy host cell ZA9710737B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1996/005280 WO1998023748A1 (fr) 1996-11-29 1996-11-29 Procede de prevention de rejet de greffon dans une transplantation et de production d'une cellule hote universelle de therapie genique a partir du gene d'activation des lymphocytes (lag-3)

Publications (1)

Publication Number Publication Date
ZA9710737B true ZA9710737B (en) 1998-07-30

Family

ID=8166413

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710737A ZA9710737B (en) 1996-11-29 1997-11-28 Methods for preventing graft rejection in transplantation and for procuding a universal gene therapy host cell

Country Status (19)

Country Link
US (1) US6500422B2 (fr)
EP (1) EP0941329B1 (fr)
JP (1) JP3920928B2 (fr)
KR (1) KR100481230B1 (fr)
AR (1) AR018489A1 (fr)
AT (1) ATE271607T1 (fr)
AU (1) AU733825B2 (fr)
BR (1) BR9612821A (fr)
CA (1) CA2272130C (fr)
DE (1) DE69632967T2 (fr)
DK (1) DK0941329T3 (fr)
EA (1) EA003772B1 (fr)
ES (1) ES2225901T3 (fr)
IL (1) IL130168A (fr)
NO (1) NO324378B1 (fr)
PT (1) PT941329E (fr)
UA (1) UA73270C2 (fr)
WO (1) WO1998023748A1 (fr)
ZA (1) ZA9710737B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941329B1 (fr) * 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Procede de prevention de rejet de greffon dans une transplantation et de production d'une cellule hote universelle de therapie genique a partir du gene d'activation des lymphocytes (lag-3)
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP2044949A1 (fr) * 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
DK3356411T3 (da) 2015-10-02 2021-09-06 Hoffmann La Roche Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
EP4201953A1 (fr) 2017-04-03 2023-06-28 F. Hoffmann-La Roche AG Immunoconjugués d'un anticorps anti-pd-1 avec une il-2 mutante ou avec l'il-15
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Traitement de tumeurs positives pour lag-3
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
DK0758383T3 (da) 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
EP0941329B1 (fr) * 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Procede de prevention de rejet de greffon dans une transplantation et de production d'une cellule hote universelle de therapie genique a partir du gene d'activation des lymphocytes (lag-3)

Also Published As

Publication number Publication date
WO1998023748A1 (fr) 1998-06-04
NO992569D0 (no) 1999-05-27
IL130168A0 (en) 2000-06-01
JP2001505770A (ja) 2001-05-08
JP3920928B2 (ja) 2007-05-30
EP0941329A1 (fr) 1999-09-15
US6500422B2 (en) 2002-12-31
AR018489A1 (es) 2001-11-28
EA199900507A1 (ru) 2000-02-28
CA2272130C (fr) 2007-10-23
AU733825B2 (en) 2001-05-24
DK0941329T3 (da) 2004-11-29
AU1066797A (en) 1998-06-22
KR20000053291A (ko) 2000-08-25
IL130168A (en) 2006-09-05
KR100481230B1 (ko) 2005-04-07
US20020081282A1 (en) 2002-06-27
EP0941329B1 (fr) 2004-07-21
HK1023599A1 (en) 2000-09-15
ATE271607T1 (de) 2004-08-15
CA2272130A1 (fr) 1998-06-04
BR9612821A (pt) 2000-04-11
DE69632967T2 (de) 2005-08-11
PT941329E (pt) 2004-11-30
EA003772B1 (ru) 2003-08-28
NO992569L (no) 1999-05-27
DE69632967D1 (de) 2004-08-26
ES2225901T3 (es) 2005-03-16
NO324378B1 (no) 2007-10-01
UA73270C2 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
GB2342007B (en) Method and apparatus for reading out leafs of ATM cells
HUP9904529A3 (en) Cell/tissue culturing device and method
IL126126A0 (en) Artificial chromosomes uses thereof and methods for preparing artificial chromosomes
AU2247699A (en) Cell control method and apparatus
AU1839395A (en) Card creation system and method
AU3950295A (en) Filter cells providing lifting means and related methods
GB2292828B (en) Method and system for charging portable rechargeable batteries
AU4483097A (en) Apparatus and method for making laminated rechargeable battery cells
EP0691038A4 (fr) Procede et appareil utilises pour recharger des accumulateurs
AU4154096A (en) Battery charging method and charger
AU6478596A (en) Method and apparatus for charging batteries
AU2731497A (en) Electrolytic system and cell
AU2801097A (en) Blast resistant and blast directing container assemblies
AU3324697A (en) Charging system and method
AU1941899A (en) A lipase expressed in endothelial cells and methods for its use
IL130168A0 (en) Genetically engineered cells comprising DNA expressing LAG-3 and their use
AU2687397A (en) Method and reagents for testing for mutations in the brca1 gene
AU2195095A (en) Devices and methods for implanting transduced cells
AU4378996A (en) Cell compositions for use in transplantation and ex vivo gene therapy
AP9801353A0 (en) Meth d and appar tus f r pre aring an acellular red blood cell substitute
AU1864999A (en) Methods and compositions for improving the success of cell transplantation in a host
HU9602862D0 (en) Arrangement and method for charging accumulators
AU1540197A (en) Method and apparatus for culturing cells and tissues
AU3518695A (en) Gene therapy for transplantation and inflammatory or thrmbotic conditions
AU4551597A (en) Controlled gene expression in plants